Alpha-conotoxins act on postsynaptic membranes, they bind to the nicotinic acetylcholine receptors (nAChR) and thus inhibit them. This toxin shows high activity on alpha-9-alpha-10 (CHRNA9-CHRNA10) (IC(50)=9.79 nM) (PubMed:26074268). It also shows weak activity on alpha-3-beta-2 (CHRNA3-CHRNB2) (IC(50)~1 uM), alpha-6/alpha-3-beta-2-beta-3 (CHRNA6/CHRNA3-CHRNB2-CHRNB3) (IC(50)~1 uM) (PubMed:26074268). The toxin binds to the same or overlapping binding sites than conotoxin RgIA (AC P0C1D0) (PubMed:26074268). Expressed by the venom duct. The cysteine framework is VIII (C-C-C-C-C-C-C-C-C-C). Contains 5 disulfide bonds. The predominant peptide contains 2 hydroxyprolines, while 2 minor peptides contains 1 and 3 hydroxyprolines. Monoisotopic mass, predominant peptide with 2 hydroxyprolines and 5 disulfide bonds. Monoisotopic mass, minor peptide with 1 hydroxyproline and 5 disulfide bonds. Monoisotopic mass, minor peptide with 3 hydroxyprolines and 5 disulfide bonds. Shows no or weak activities on 5-hydroxytryptamine receptor 3A (HTR3A), and alpha-1-beta-1-delta-epsilon (CHRNA1-CHRNB1-CHRND-CHRNE), alpha-3 beta-4 (CHRNA3-CHRNB4), alpha-4 beta-2 (CHRNA3-CHRNB2), and alpha-7/CHRNA7 nAChR. Belongs to the conotoxin S superfamily.